MA42624A - Dérivés de benzodiazépine, compositions et méthodes de traitement de la déficience cognitive - Google Patents
Dérivés de benzodiazépine, compositions et méthodes de traitement de la déficience cognitiveInfo
- Publication number
- MA42624A MA42624A MA042624A MA42624A MA42624A MA 42624 A MA42624 A MA 42624A MA 042624 A MA042624 A MA 042624A MA 42624 A MA42624 A MA 42624A MA 42624 A MA42624 A MA 42624A
- Authority
- MA
- Morocco
- Prior art keywords
- compositions
- treatment methods
- benzodiazepine derivatives
- cognitive deficiency
- cognitive
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/12—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains three hetero rings
- C07D487/14—Ortho-condensed systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/13—Amines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
- A61K31/27—Esters, e.g. nitroglycerine, selenocyanates of carbamic or thiocarbamic acids, meprobamate, carbachol, neostigmine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/445—Non condensed piperidines, e.g. piperocaine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
- A61K31/551—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having two nitrogen atoms, e.g. dilazep
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
- A61K31/551—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having two nitrogen atoms, e.g. dilazep
- A61K31/5513—1,4-Benzodiazepines, e.g. diazepam or clozapine
- A61K31/5517—1,4-Benzodiazepines, e.g. diazepam or clozapine condensed with five-membered rings having nitrogen as a ring hetero atom, e.g. imidazobenzodiazepines, triazolam
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201562182336P | 2015-06-19 | 2015-06-19 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| MA42624A true MA42624A (fr) | 2021-04-28 |
Family
ID=57546444
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MA042624A MA42624A (fr) | 2015-06-19 | 2016-06-17 | Dérivés de benzodiazépine, compositions et méthodes de traitement de la déficience cognitive |
Country Status (13)
| Country | Link |
|---|---|
| US (3) | US10815242B2 (fr) |
| EP (1) | EP3310785A4 (fr) |
| JP (2) | JP6987384B2 (fr) |
| CN (2) | CN108026107B (fr) |
| AU (2) | AU2016279052A1 (fr) |
| CA (1) | CA2990004A1 (fr) |
| EA (1) | EA036844B1 (fr) |
| HK (1) | HK1254362A1 (fr) |
| IL (1) | IL256354B (fr) |
| MA (1) | MA42624A (fr) |
| MX (2) | MX2017015752A (fr) |
| WO (1) | WO2016205739A1 (fr) |
| ZA (1) | ZA201800360B (fr) |
Families Citing this family (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN106068256B (zh) | 2013-12-20 | 2020-10-23 | 艾吉因生物股份有限公司 | 用于治疗认知损害的苯并二氮杂*衍生物、组合物和方法 |
| EP3310785A4 (fr) | 2015-06-19 | 2018-12-26 | Agenebio, Inc. | Dérivés de benzodiazépine, compositions et méthodes de traitement de la déficience cognitive |
| US20180170941A1 (en) * | 2016-12-19 | 2018-06-21 | Agenebio, Inc. | Benzodiazepine derivatives, compositions, and methods for treating cognitive impairment |
| BR112019012821A2 (pt) | 2016-12-19 | 2019-11-26 | Agenebio Inc | derivados de benzodiazepina, composições e métodos para o tratamento do comprometimento cognitivo |
| CA3104478A1 (fr) * | 2018-06-19 | 2019-12-26 | Agenebio, Inc. | Derives de benzodiazepine, compositions, et methodes de traitement de deficience cognitive |
| IL294031A (en) * | 2019-12-19 | 2022-08-01 | Agenebio Inc | History of benzodiazepines, preparations and methods for the treatment of cognitive impairment |
| CA3185573A1 (fr) * | 2020-07-10 | 2022-01-13 | Deepa GANDLA | Polymorphes d'un agoniste gabaa ?5 et methodes d'utilisation dans le traitement d'une deficience cognitive |
| WO2024039886A1 (fr) | 2022-08-19 | 2024-02-22 | Agenebio, Inc. | Dérivés de benzoazépine, compositions et méthodes de traitement de déficience cognitive |
Family Cites Families (82)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US3391142A (en) | 1966-02-09 | 1968-07-02 | Lilly Co Eli | Adamantyl secondary amines |
| US3539573A (en) | 1967-03-22 | 1970-11-10 | Jean Schmutz | 11-basic substituted dibenzodiazepines and dibenzothiazepines |
| ES413944A1 (es) | 1972-04-20 | 1976-06-01 | Merz & Co | Procedimiento para la preparacion de compuestos de adamen- tano trisustituidos en las posiciones 1,3,5. |
| NL7605526A (nl) | 1976-05-24 | 1977-11-28 | Akzo Nv | Nieuwe tetracyclische derivaten. |
| JPS54130587A (en) | 1978-03-30 | 1979-10-09 | Otsuka Pharmaceut Co Ltd | Carbostyryl derivative |
| DE2856393C2 (de) | 1978-12-27 | 1983-04-28 | Merz + Co GmbH & Co, 6000 Frankfurt | Arzneimittel zur Behandlung von Morbus Parkinson |
| US4804663A (en) | 1985-03-27 | 1989-02-14 | Janssen Pharmaceutica N.V. | 3-piperidinyl-substituted 1,2-benzisoxazoles and 1,2-benzisothiazoles |
| IE58370B1 (en) | 1985-04-10 | 1993-09-08 | Lundbeck & Co As H | Indole derivatives |
| GB8607684D0 (en) | 1986-03-27 | 1986-04-30 | Ici America Inc | Thiazepine compounds |
| US4816456A (en) | 1986-10-01 | 1989-03-28 | Summers William K | Administration of monoamine acridines in cholinergic neuronal deficit states |
| HU201906B (en) | 1987-03-04 | 1991-01-28 | Sandoz Ag | Process for producing phenyl-carbamate derivative and acid additional salts and pharmaceutical compositions containing them |
| FI95572C (fi) | 1987-06-22 | 1996-02-26 | Eisai Co Ltd | Menetelmä lääkeaineena käyttökelpoisen piperidiinijohdannaisten tai sen farmaseuttisen suolan valmistamiseksi |
| US4831031A (en) | 1988-01-22 | 1989-05-16 | Pfizer Inc. | Aryl piperazinyl-(C2 or C4) alkylene heterocyclic compounds having neuroleptic activity |
| US5006528A (en) | 1988-10-31 | 1991-04-09 | Otsuka Pharmaceutical Co., Ltd. | Carbostyril derivatives |
| CA2000786C (fr) | 1988-11-07 | 1999-01-26 | Cornelus G. M. Janssen | 3-piperidinyl-1,2-benzisoxazoles |
| US5043345A (en) | 1989-02-22 | 1991-08-27 | Novo Nordisk A/S | Piperidine compounds and their preparation and use |
| ES2059602T3 (es) | 1989-04-14 | 1994-11-16 | Merz & Co Gmbh & Co | Uso de derivados de adamantano para la prevencion y tratamiento de isquemia cerebral. |
| EP0402644B1 (fr) | 1989-05-19 | 1995-08-16 | Hoechst-Roussel Pharmaceuticals Incorporated | N-(aryloxyalkyl)hétéroarylpipéridines et -hétéroarylpipérazines, leur procédé de préparation et leur application comme médicaments |
| US5229382A (en) | 1990-04-25 | 1993-07-20 | Lilly Industries Limited | 2-methyl-thieno-benzodiazepine |
| JP2807577B2 (ja) | 1990-06-15 | 1998-10-08 | エーザイ株式会社 | 環状アミド誘導体 |
| JP2800953B2 (ja) | 1990-07-06 | 1998-09-21 | 住友製薬株式会社 | 新規なイミド誘導体 |
| EP0478195B1 (fr) | 1990-09-21 | 1999-05-26 | Rohm And Haas Company | Dihydropyridazinones et pyridazinones comme fongicides |
| US5190951A (en) | 1990-10-19 | 1993-03-02 | Ss Pharmaceutical Co., Ltd. | Quinoline derivatives |
| WO1992020682A1 (fr) | 1991-05-24 | 1992-11-26 | E.I. Du Pont De Nemours And Company | Anilides arthropodicides |
| US5106856A (en) | 1991-06-07 | 1992-04-21 | Hoechst-Roussel Pharmaceuticals Inc. | [(Arylalkylpiperidin-4-yl)methyl]-2a,3,4,5-tetrahydro-1(2H)-acenaphthylen-1-ones and related compounds |
| TW201311B (fr) * | 1991-06-17 | 1993-03-01 | Hoffmann La Roche | |
| US5312925A (en) | 1992-09-01 | 1994-05-17 | Pfizer Inc. | Monohydrate of 5-(2-(4-(1,2-benzisothiazol-3-yl)-1-piperazinyl)-ethyl)-6-chloro-1,3-dihydro-2H-indol-2-one-hydrochloride |
| PL180465B1 (pl) | 1994-03-02 | 2001-02-28 | Akzo Nobel Nv | Kompozycja farmaceutyczna zawierajaca trans-5-chloro-2-metylo-2,3,3a,12b-tetrahydro-1H-dibenz[2,3:6,7]oksepino[4,5-c]pirol PL PL PL |
| US6479523B1 (en) | 1997-08-26 | 2002-11-12 | Emory University | Pharmacologic drug combination in vagal-induced asystole |
| AU1041599A (en) | 1997-11-13 | 1999-06-07 | Jose Luis Castro Pineiro | Therapeutic uses of triazolo-pyridazine derivatives |
| US6294583B1 (en) | 1998-01-13 | 2001-09-25 | Synchroneuron, Llc | Methods of treating tardive dyskinesia and other movement disorders |
| US6391922B1 (en) | 1998-01-13 | 2002-05-21 | Synchroneuron, Llc | Treatment of posttraumatic stress disorder, obsessive-compulsive disorder and related neuropsychiatric disorders |
| WO2000027849A2 (fr) | 1998-11-12 | 2000-05-18 | Merck & Co., Inc. | Polymorphes therapeutiques d'un agoniste inverse de gaba-a alpha-5 et formulations de pamoate de ceux-ci |
| AU2825600A (en) | 1999-03-03 | 2000-09-21 | Eisai Co. Ltd. | Fluorides of 4-substituted piperidine derivatives |
| GB9911802D0 (en) | 1999-05-20 | 1999-07-21 | Merck Sharp & Dohme | Therapeutic combination |
| GB9911803D0 (en) | 1999-05-20 | 1999-07-21 | Merck Sharp & Dohme | Therapeutic combination |
| GB9911804D0 (en) | 1999-05-20 | 1999-07-21 | Merck Sharp & Dohme | Therapeutic combination |
| GB9929569D0 (en) | 1999-12-14 | 2000-02-09 | Merck Sharp & Dohme | Therapeutic agents |
| GB0004297D0 (en) | 2000-02-23 | 2000-04-12 | Ucb Sa | 2-oxo-1 pyrrolidine derivatives process for preparing them and their uses |
| US20020151591A1 (en) | 2000-10-17 | 2002-10-17 | Anabella Villalobos | Combination use of acetylcholinesterase inhibitors and GABAa inverse agonists for the treatment of cognitive disorders |
| TWI239333B (en) | 2000-11-16 | 2005-09-11 | Hoffmann La Roche | Benzodiazepine derivatives as GABA A receptor modulators |
| PA8535601A1 (es) | 2000-12-21 | 2002-11-28 | Pfizer | Derivados benzimidazol y piridilimidazol como ligandos para gabaa |
| CZ20032338A3 (cs) | 2001-03-01 | 2004-08-18 | Pfizeráproductsáinc | Použití inversních agonistů GABA A v kombinaci s parciálními agonisty receptoru nikotinuŹ estrogenemŹ selektivními modulátory estrogenu nebo vitaminem E při léčení kognitivních poruch |
| US6686352B2 (en) | 2001-05-18 | 2004-02-03 | Hoffmann-La Roche Inc. | Substituted imidazo [1,5-a] pyrimido [5,4-d] [1] benzazepine derivatives |
| US20050071088A1 (en) | 2001-08-13 | 2005-03-31 | Landfield Philip W | Gene expression profile biomarkers and therapeutic targets for brain aging and age-related cognitive impairment |
| WO2003061656A1 (fr) | 2002-01-16 | 2003-07-31 | Endo Pharmaceuticals Inc. | Composition pharmaceutique et methode de traitement de troubles du systeme nerveux central |
| GB0218876D0 (en) | 2002-08-13 | 2002-09-25 | Merck Sharp & Dohme | Therapeutic agents |
| EP1532120B1 (fr) | 2002-08-13 | 2009-01-14 | MERCK SHARP & DOHME LTD. | Derives de phenylpyridazine utilises en tant que ligands pour des recepteurs gaba |
| US7635709B2 (en) | 2002-09-26 | 2009-12-22 | The United States Of America As Represented By The Department Of Veterans Affairs | Compositions and methods for bowel care in individuals with chronic intestinal pseudo-obstruction |
| CN100339070C (zh) | 2002-10-24 | 2007-09-26 | 莫茨药物股份两合公司 | 包含1－氨基环己烷衍生物类和乙酰胆碱酯酶抑制剂类的药物组合物 |
| EP1567674A4 (fr) | 2002-11-22 | 2007-09-26 | Univ Johns Hopkins | Cible destinee a la therapie d'un trouble cognitif |
| ATE411015T1 (de) | 2003-10-22 | 2008-10-15 | Merz Pharma Gmbh & Co Kgaa | Verwendung von 1-aminocyclohexan-derivaten zur modifizierung der abscheidung von fibrillogenen as peptiden in amyloidpathien |
| CA2578953A1 (fr) | 2004-09-23 | 2006-03-30 | Merz Pharma Gmbh & Co. Kgaa | Memantine pour le traitement des troubles du comportement de l'enfant |
| ES2312022T3 (es) * | 2004-10-12 | 2009-02-16 | F. Hoffmann-La Roche Ag | Derivados de imidazo (1,5-a-triazolo (1,5-dibenzodiapeina para el tratamiento e trastornos cognitivos. |
| KR100923399B1 (ko) * | 2004-10-20 | 2009-10-23 | 에프. 호프만-라 로슈 아게 | 이미다조-벤조다이아제핀 유도체 |
| RU2007114763A (ru) | 2004-10-20 | 2008-11-27 | Ф.Хоффманн-Ля Рош Аг (Ch) | Галогенозамещенные производные бензодиазепинов |
| WO2006063708A1 (fr) * | 2004-12-14 | 2006-06-22 | F.Hoffmann-La Roche Ag | Imidazo-benzodiazepines tetracycliques en tant que modulateurs des recepteurs gaba |
| US20060205822A1 (en) | 2004-12-22 | 2006-09-14 | Forest Laboratories, Inc. | 1-Aminocyclohexane derivatives for the treatment of multiple sclerosis, emotional lability and pseudobulbar affect |
| AU2006276998A1 (en) | 2005-05-16 | 2007-02-15 | Wisys Technology Foundation, Inc. | Gabaergic agents to treat memory deficits |
| US8510055B2 (en) | 2005-08-03 | 2013-08-13 | The Johns Hopkins University | Methods for characterizing and treating cognitive impairment in aging and disease |
| EP2682481A3 (fr) | 2005-08-03 | 2014-09-17 | The Johns-Hopkins University | Procédés de caractérisation et de traitement de la déficience cognitive lors du vieillissement et de la maladie |
| KR101009860B1 (ko) | 2005-10-11 | 2011-01-19 | 에프. 호프만-라 로슈 아게 | 이미다조 벤조다이아제핀 유도체 |
| US20070112017A1 (en) | 2005-10-31 | 2007-05-17 | Braincells, Inc. | Gaba receptor mediated modulation of neurogenesis |
| US8486979B2 (en) | 2006-12-12 | 2013-07-16 | Abbvie Inc. | 1,2,4 oxadiazole compounds and methods of use thereof |
| US7943619B2 (en) | 2007-12-04 | 2011-05-17 | Hoffmann-La Roche Inc. | Isoxazolo-pyridazine derivatives |
| AU2009277086B2 (en) | 2008-08-01 | 2015-12-10 | Lixte Biotechnology, Inc. | Neuroprotective agents for the prevention and treatment of neurodegenerative diseases |
| US20110136762A1 (en) | 2008-09-24 | 2011-06-09 | E.I. Du Pont De Nemours And Company | Fungicidal pyridazines |
| CA2737452C (fr) | 2008-09-25 | 2018-05-22 | Vive Nano Inc. | Procedes de production de nanoparticules de polymere et formulations d'ingredients actifs |
| JP2012524065A (ja) | 2009-04-17 | 2012-10-11 | ゼノポート，インコーポレーテッド | ＧＡＢＡＢ受容体リガンドとしてのγ−アミノ酪酸誘導体 |
| CA2786716A1 (fr) | 2010-01-11 | 2011-07-14 | Mithridion, Inc. | Composes et compositions pour l'amelioration de la cognition, leurs procedes de fabrication, et methodes de traitement |
| WO2012059482A1 (fr) * | 2010-11-05 | 2012-05-10 | F. Hoffmann-La Roche Ag | Utilisation de composés pharmaceutiques actifs pour le traitement d'états du système nerveux central |
| JP5916746B2 (ja) | 2010-11-15 | 2016-05-11 | エージンバイオ， インコーポレイテッド | 認知障害を処置するためのピリダジン誘導体、組成物、および方法 |
| BR112013012072A2 (pt) | 2010-11-15 | 2016-08-16 | Agenebio Inc | derivados, composições de benzodiazepina e métodos para o tratamento de danos cognitivos |
| JPWO2012161133A1 (ja) | 2011-05-20 | 2014-07-31 | 日産化学工業株式会社 | 置換ピリダジン化合物及び農園芸用殺菌剤 |
| US20150374705A1 (en) * | 2012-02-14 | 2015-12-31 | Shanghai Institues for Biological Sciences | Substances for treatment or relief of pain |
| US20150224094A1 (en) | 2012-09-10 | 2015-08-13 | Ophirex, Inc. | Administration of acetylcholinesterase inhibitors to mitigate neurotoxin-induced paralysis and residual neuromuscular blockade |
| CN106068256B (zh) | 2013-12-20 | 2020-10-23 | 艾吉因生物股份有限公司 | 用于治疗认知损害的苯并二氮杂*衍生物、组合物和方法 |
| EP3310785A4 (fr) | 2015-06-19 | 2018-12-26 | Agenebio, Inc. | Dérivés de benzodiazépine, compositions et méthodes de traitement de la déficience cognitive |
| US20180170941A1 (en) | 2016-12-19 | 2018-06-21 | Agenebio, Inc. | Benzodiazepine derivatives, compositions, and methods for treating cognitive impairment |
| BR112019012821A2 (pt) | 2016-12-19 | 2019-11-26 | Agenebio Inc | derivados de benzodiazepina, composições e métodos para o tratamento do comprometimento cognitivo |
| CN108567787A (zh) | 2017-03-10 | 2018-09-25 | 辛衍雪 | 一种治疗慢性阻塞性肺病的药物组合物 |
| CA3104478A1 (fr) | 2018-06-19 | 2019-12-26 | Agenebio, Inc. | Derives de benzodiazepine, compositions, et methodes de traitement de deficience cognitive |
-
2016
- 2016-06-17 EP EP16812577.1A patent/EP3310785A4/fr active Pending
- 2016-06-17 CN CN201680042224.6A patent/CN108026107B/zh active Active
- 2016-06-17 MX MX2017015752A patent/MX2017015752A/es unknown
- 2016-06-17 MA MA042624A patent/MA42624A/fr unknown
- 2016-06-17 CN CN202110582826.3A patent/CN113264939A/zh active Pending
- 2016-06-17 US US15/736,697 patent/US10815242B2/en active Active
- 2016-06-17 WO PCT/US2016/038224 patent/WO2016205739A1/fr active Application Filing
- 2016-06-17 EA EA201890090A patent/EA036844B1/ru not_active IP Right Cessation
- 2016-06-17 AU AU2016279052A patent/AU2016279052A1/en not_active Abandoned
- 2016-06-17 IL IL256354A patent/IL256354B/en unknown
- 2016-06-17 MX MX2020013374A patent/MX2020013374A/es unknown
- 2016-06-17 CA CA2990004A patent/CA2990004A1/fr active Granted
- 2016-06-17 JP JP2017565726A patent/JP6987384B2/ja active Active
-
2018
- 2018-01-18 ZA ZA2018/00360A patent/ZA201800360B/en unknown
- 2018-10-19 HK HK18113438.3A patent/HK1254362A1/zh unknown
-
2020
- 2020-09-22 US US17/028,917 patent/US11312721B2/en active Active
-
2021
- 2021-01-13 AU AU2021200164A patent/AU2021200164B2/en active Active
- 2021-06-24 JP JP2021105189A patent/JP2021152071A/ja not_active Withdrawn
-
2022
- 2022-02-04 US US17/592,679 patent/US20220274996A1/en active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| EA036844B1 (ru) | 2020-12-28 |
| IL256354A (en) | 2018-02-28 |
| US20190055258A1 (en) | 2019-02-21 |
| CA2990004A1 (fr) | 2016-12-22 |
| HK1254362A1 (zh) | 2019-07-19 |
| US20220274996A1 (en) | 2022-09-01 |
| CN108026107A (zh) | 2018-05-11 |
| JP2018521034A (ja) | 2018-08-02 |
| US20210009602A1 (en) | 2021-01-14 |
| EA201890090A1 (ru) | 2018-09-28 |
| AU2021200164A1 (en) | 2021-03-18 |
| EP3310785A4 (fr) | 2018-12-26 |
| IL256354B (en) | 2022-09-01 |
| MX2017015752A (es) | 2018-04-13 |
| US10815242B2 (en) | 2020-10-27 |
| US11312721B2 (en) | 2022-04-26 |
| ZA201800360B (en) | 2023-03-29 |
| CN108026107B (zh) | 2021-07-30 |
| CN113264939A (zh) | 2021-08-17 |
| AU2021200164B2 (en) | 2022-09-08 |
| MX2020013374A (es) | 2022-05-06 |
| JP6987384B2 (ja) | 2021-12-22 |
| AU2016279052A1 (en) | 2018-02-15 |
| EP3310785A1 (fr) | 2018-04-25 |
| JP2021152071A (ja) | 2021-09-30 |
| WO2016205739A1 (fr) | 2016-12-22 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| IL264049A (en) | Compounds, preparations and methods for treating the disease | |
| MA45188A (fr) | Oligonucléotides, compositions et méthodes associées | |
| MA42624A (fr) | Dérivés de benzodiazépine, compositions et méthodes de traitement de la déficience cognitive | |
| IL264156A (en) | Compounds, preparations and methods for treating the disease | |
| SG11201705093UA (en) | Composition for treating il-6-related diseases | |
| IL253979B (en) | Methods, preparations and kits for cancer treatment | |
| BR112017018413A2 (pt) | tratamento de pancreatite | |
| MA54254A (fr) | Dérivés de benzodiazépine cytotoxique | |
| ZA201605027B (en) | Benzodiazepine derivatives, compositions, and methods for treating cognitive impairment | |
| MA41898A (fr) | Dérivés de quinazolinone bicyclique | |
| IL267451A (en) | Benzodiazepine derivatives, compounds, and methods for treating cognitive impairment | |
| PT3353167T (pt) | Moduladores da indolamina 2,3-dioxigenase | |
| CL2015000926A1 (es) | Proceso para la elaboración de compuestos para el tratamiento del cancer derivados de azetidin-1-il-metanona y compuestos intermediarios. | |
| DK3307267T3 (da) | Behandling af multipel sklerose | |
| EA201790156A1 (ru) | Азетидинилоксифенилпирролидиновые соединения | |
| MX2018005987A (es) | Compuestos heterociclicos para el tratamiento de enfermedades. | |
| MA50062A (fr) | Méthodes permettant de traiter la dystrophie musculaire | |
| DK3302478T3 (da) | Pac-1 kombinations behandling | |
| MA40687A (fr) | Méthodes et compositions de traitement de malformation vasculaire | |
| BR112016015712A2 (pt) | método de tratamento de doenças hepáticas. | |
| MA42679A (fr) | Dérivés de pyrrolidin-2-one annelés antibactériens | |
| DK3294769T3 (da) | Behandling for multipelt myelom (mm) | |
| ES2966458T3 (es) | Procedimiento de tratamiento de aceites usados | |
| IL256236A (en) | Derived from anus for the treatment of bacterial infections | |
| DK3302573T3 (da) | Sammensætning til behandlingen af hjernelæsioner |